Page last updated: 2024-12-07

n-acetylcysteinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID10176265
SCHEMBL ID377413
MeSH IDM0467636

Synonyms (34)

Synonym
n-acetylcysteinamide
AKOS006373417
n-acetylcysteine amide
3-isatoicanhydridecarboxylicacidmethylester
naca
acetylcysteinamide
38520-57-9
n-acetyl-l-cysteinamide
unii-4n69717rkw
4n69717rkw ,
acetylcysteine amide
propanamide, 2-(acetylamino)-3-mercapto-, (r)-
nac amide
n-acetyl-l-cysteine amide
propanamide, 2-(acetylamino)-3-mercapto-, (2r)-
n-acetyl-cysteine-amide
n-acetylcysteine amide [who-dd]
n-acetyl cysteine amide
(r)-2-acetamido-3-mercaptopropanamide
S5804
SCHEMBL377413
DTXSID30436398
mfcd01696115
n-acetylcysteine amide, >=98% (hplc)
(2r)-2-(acetylamino)-3-mercaptopropanamide
HY-110256
CS-0033121
UJCHIZDEQZMODR-BYPYZUCNSA-N
n-acetylcysteine amide;(r)-2-acetamido-3-mercaptopropanamide
(2r)-2-acetamido-3-sulfanylpropanamide
DB14480
Q15408428
ac-cys-nh2
HMS3886B05

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It is safe at therapeutic doses, but its overdose can result in severe hepatotoxicity, a leading cause of drug-induced acute liver failure in the USA."( N-acetylcysteine amide, a promising antidote for acetaminophen toxicity.
Ercal, N; Hart, M; Khayyat, A; Tobwala, S, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" It has emerged as a promising thiol antioxidant for multiple indications; however, the pharmacokinetic property is yet unclear due to lack of an accurate quantification method."( Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method.
Ginman, T; Hassan, M; He, R; Norgren, S; Ottosson, H; Zhao, Y; Zheng, W, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" In view of these developments, we investigated whether a HAART drug combination of 3'-azido-2',3'-deoxythymidine (AZT) and indinavir (IDV) can alter the functionality of the blood-brain barrier (BBB) endothelial cells, thereby exacerbating this condition."( Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells.
Banerjee, A; Banks, WA; Ercal, N; Manda, KR, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" Superior bioavailability of NACA is likely to fulfill the promises of NAC as well as a molecule to improve the endurance and resident time of bioscaffolds and biomaterials."( N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine.
Girish, KS; Hemshekhar, M; Kemparaju, K; Santhosh, MS; Sunitha, K; Thushara, RM; Yariswamy, M, 2013
)
0.39
" However, this approach has been hindered by the low CNS bioavailability of NAC."( N-acetylcysteine amide confers neuroprotection, improves bioenergetics and behavioral outcome following TBI.
Goldstein, GA; Pandya, JD; Patel, SP; Pauly, JR; Rabchevsky, AG; Readnower, RD; Sullivan, PG; Yonutas, HM, 2014
)
0.4
" Therefore, we studied the protective effects of N-acetylcysteineamide (NACA), a novel antioxidant, with higher bioavailability and compared it with NAC in APAP-induced hepatotoxicity in a human-relevant in vitro system, HepaRG."( Comparative evaluation of N-acetylcysteine and N-acetylcysteineamide in acetaminophen-induced hepatotoxicity in human hepatoma HepaRG cells.
Ercal, N; Fan, W; Khayyat, A; Tobwala, S, 2015
)
0.42
" N-acetylcysteine (NAC) has limited but well-documented neuroprotective effects after experimental central nervous system ischemia and TBI, but its bioavailability is very low."( Neuroprotective effects of N-acetylcysteine amide on experimental focal penetrating brain injury in rats.
Davidsson, J; Günther, M; Mathiesen, T; Norgren, S; Plantman, S; Risling, M, 2015
)
0.42
" The method was utilized in pharmacokinetic study which showed that the bioavailability of NACA is significantly higher than NAC (67% and 15%, respectively)."( Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method.
Ginman, T; Hassan, M; He, R; Norgren, S; Ottosson, H; Zhao, Y; Zheng, W, 2020
)
0.56
" Nevertheless, NAC has low membrane permeability and poor bioavailability and its limited delivery to the brain may explain inconsistencies in the literature."( Effects of N-acetylcysteine amide on anxiety and stress behavior in zebrafish.
Benvenutti, R; Elisabetsky, E; Herrmann, AP; Marcon, M; Mocelin, R; Piato, A; Reis, CG; Sachett, A, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" For synaptic and non-synaptic mitochondria, only 300mg/kg NACA dosage showed efficacy."( N-acetylcysteine amide preserves mitochondrial bioenergetics and improves functional recovery following spinal trauma.
Eldahan, KC; Goldstein, GA; Magnuson, DS; Morehouse, J; Pandya, JD; Patel, SP; Rabchevsky, AG; Sullivan, PG; VanRooyen, JL; Yonutas, HM, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (29.03)29.6817
2010's35 (56.45)24.3611
2020's9 (14.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.17%)5.53%
Reviews2 (3.17%)6.00%
Case Studies1 (1.59%)4.05%
Observational0 (0.00%)0.25%
Other58 (92.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]